Greenwich LifeSciences Overhauls FLAMINGO-01 Trial Design to Boost Success Probability
Event summary
- FLAMINGO-01 Data Safety Monitoring Board recommended continuation of the study without modification in May 2026.
- Study design modifications, including increased enrollment size and rate, received FDA and EMA approval to enhance trial power and reduce risk.
- Enrollment rate is expected to more than double (122% increase), accelerating event rate and potentially shortening time to interim analysis.
- Company reports screening over 1,500 patients across 170-180 sites in 11 countries, with plans to expand into Norway, Denmark, Sweden, UK, and Canada.
The big picture
Greenwich LifeSciences is repositioning FLAMINGO-01 to mirror large pharma trial standards, aiming for higher success probabilities and investor appeal. The modifications align with industry benchmarks like Kadcyla's Katherine study and Enhertu's Destiny Breast-05, targeting a potential $10 billion revenue market by expanding into non-HLA-A*02 populations. The company's disciplined burn rate management suggests operational efficiency amid clinical scaling.
What we're watching
- Trial Execution Risk
- Whether the accelerated enrollment and modified trial design can sustain the low event rate observed thus far.
- Regulatory Flexibility
- How UK and Canadian regulatory authorities may further influence FLAMINGO-01's study parameters.
- Strategic Partnerships
- The pace at which Greenwich LifeSciences can secure non-dilutive funding through licensing or debt/royalty financing.
Related topics